Corazon (. D. Sanders - Jun 7, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Jun 7, 2023
Transactions value $
-$76,700
Form type
4
Date filed
6/9/2023, 02:31 PM
Previous filing
Jun 29, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +3.86K +53.65% $0.00 11.1K Jun 7, 2023 Direct F1
transaction RARE Common Stock Sale -$76.7K -1.49K -13.43% $51.65 9.57K Jun 8, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Award $0 +7.11K $0.00 7.11K Jun 7, 2023 Common Stock 7.11K $51.82 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024.
F2 The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
F3 The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024.